Neurogene Inc. (NGNE) has disclosed a new risk, in the Corporate Activity and Growth category.Don't Miss out on Research Tools:Discover the ...

Neurogene (NGNE) announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of ...

Monday closed up +0.39%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) ...

Neurogene (NASDAQ:NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy ...

Neurogene NGNE stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the pharmaceutical company’s shares to drop massively in after-hours trading, and they ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Research reports are not currently available for NGNE.

24 x 32 cm. (9.4 x 12.6 in.) ...

Invest in the best stocks under $50 with Interactive Brokers for fast trade execution. You don’t need thousands of dollars in the bank to get started investing. Just $50, or less, can help you ...